Fesoterodine — Discount Pricing
Fesoterodine is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Fesoterodine Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $139.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Fesoterodine
Fesoterodine is a prescription medication. Ask your doctor if Fesoterodine is right for you.
How to Check Fesoterodine Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Fesoterodine at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Urology
What Fesoterodine is approved for (FDA label)
Fesoterodine fumarate extended-release tablets are indicated for the treatment of: Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) 1.1 Adult Overactive Bladder Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. Pediatric use information is approved for Pfizer Inc.'s TOVIAZ ® (fesoterodine fumarate) Extended-Release Tablets. However, due to Pfizer Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Source: Read the full FDA label on DailyMed. Label effective date: July 16, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Fesoterodine (FDA label)
Extended-release tablets: Fesoterodine fumarate extended-release tablets, 4 mg are light blue, oval, biconvex film-coated; debossed with ´´F4´´ on one side and plain on other side. Fesoterodine fumarate extended-release tablets, 8 mg are blue, oval, biconvex film-coated; debossed with ´´F8´´ on one side and plain on other side. Extended-release tablets: 4 mg and 8 mg (3)
Source: FDA prescribing information (DailyMed). Set ID: b1abd9cb-c480-437b-8531-e2de3e188363. SPL document ID: 587822cb-032b-49b3-8561-e7d553e5d54f. Label effective date: July 16, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Fesoterodine (FDA label)
The following clinically significant adverse reactions are described elsewhere in labeling: Angioedema [see Warnings and Precautions (5.1)] Urinary Retention [see Warnings and Precautions (5.2)] Decreased Gastrointestinal Motility [see Warnings and Precautions (5.3)] Most frequently reported adverse events with fesoterodine fumarate extended-release tablets in adult patients with OAB (≥4%) were: dry mouth (placebo, 7%; fesoterodine fumarate extended-release tablet 4 mg, 19%; fesoterodine fumarate extended-release tablet 8 mg, 35%) and constipation (placebo, 2%; fesoterodine fumarate extended-release tablet 4 mg, 4%; fesoterodine fumarate extended-release tablet 8 mg, 6%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ascend Laboratories, LLC at 1-877-272-7901 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Pediatric use information is approved for Pfizer Inc.'s TOVIAZ® (fesoterodine fumarate) Extended-Release Tablets.
Source: FDA prescribing information (DailyMed). Set ID: b1abd9cb-c480-437b-8531-e2de3e188363. SPL document ID: 587822cb-032b-49b3-8561-e7d553e5d54f. Label effective date: July 16, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Fesoterodine (FDA label)
Fesoterodine fumarate extended-release tablets are contraindicated in patients with any of the following: known or suspected hypersensitivity to fesoterodine fumarate extended-release tablets or any of its ingredients, or to tolterodine tartrate tablets or tolterodine tartrate extended-release capsules [see Clinical Pharmacology ( 12.1 )] . Reactions have included angioedema [see Warnings and Precautions ( 5.1 )] urinary retention [see Warnings and Precautions ( 5.2 )] gastric retention [see Warnings and Precautions ( 5.3 )] uncontrolled narrow-angle glaucoma [see Warnings and Precautions ( 5.4 )] Known or suspected hypersensitivity to fesoterodine fumarate extended-release tablets or any of its ingredients or to tolterodine tartrate tablets or tolterodine tartrate extended-release capsules.(4) Urinary retention (4) Gastric retention (4) Uncontrolled narrow-angle glaucoma. (4)
Source: FDA prescribing information (DailyMed). Set ID: b1abd9cb-c480-437b-8531-e2de3e188363. SPL document ID: 587822cb-032b-49b3-8561-e7d553e5d54f. Label effective date: July 16, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Fesoterodine (FDA label)
Angioedema : Promptly discontinue fesoterodine fumarate extended-release tablets and provide appropriate therapy. (5.1) Urinary Retention : Fesoterodine fumarate extended-release tablets are not recommended in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention. (5.2) Decreased Gastrointestinal Motility : Fesoterodine fumarate extended-release tablets are not recommended for use in patients with decreased gastrointestinal motility, such as those with severe constipation. (5.3) Worsening of Narrow -Angle Glaucoma : Use fesoterodine fumarate extended-release tablets with caution in patients being treated for narrow-angle glaucoma. (5.4) Central Nervous System Effects : Somnolence has been reported with fesoterodine fumarate extended-release tablets.
Source: FDA prescribing information (DailyMed). Set ID: b1abd9cb-c480-437b-8531-e2de3e188363. SPL document ID: 587822cb-032b-49b3-8561-e7d553e5d54f. Label effective date: July 16, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Fesoterodine (FDA label)
7.1 Antimuscarinic Drugs Coadministration of fesoterodine fumarate extended-release tablets with other antimuscarinic agents that produce dry mouth, constipation, urinary retention, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. 7.2 CYP3A4 Inhibitors Doses of fesoterodine fumarate extended-release tablets greater than 4 mg are not recommended in adult patients taking strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, and clarithromycin [see Dosage and Administration ( 2.5 )]. In a study in adults, coadministration of the strong CYP3A4 inhibitor ketoconazole with fesoterodine led to approximately a doubling of the maximum concentration (C max ) and area under the concentration versus time curve (AUC) of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of fesoterodine.
Source: FDA prescribing information (DailyMed). Set ID: b1abd9cb-c480-437b-8531-e2de3e188363. SPL document ID: 587822cb-032b-49b3-8561-e7d553e5d54f. Label effective date: July 16, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.